Enterprise Value

2.031B

Cash

161.7M

Avg Qtr Burn

-31.04M

Short % of Float

0.33%

Insider Ownership

0.23%

Institutional Own.

72.37%

Qtr Updated

09/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date

PDUFA

Approval decision

Lete-cel (NY-ESO) Details
Myxoid/Round cell liposarcoma, Sarcoma

Phase 2

Data readout

Phase 2

Data readout

ADP-A2M4CD8 (MAGE A4) +/- nivolumab Details
Head and neck cancer, Bladder cancer, Cancer, Solid tumor/s, Urothelial cancer

Phase 1

Data readout

afami-cel (afamitresgene autoleucel) (ADP-A2M4) + pembro Details
Head and neck cancer, Homozygous familial hypercholesterolemia, Cancer, Solid tumor/s

Failed

Discontinued

ADP-A2AFP Details
Hepatocellular carcinoma, Cancer

Failed

Discontinued

TC-110 (CD19) Details
Non-Hodgkin lymphoma, Leukemia, Acute lymphoblastic leukemia, Diffuse large B cell lymphoma, Cancer

Failed

Discontinued

TC-510 Details
Cancer, Colorectal cancer , Ovarian cancer, Mesothelioma, Triple-negative breast cancer , Pancreatic cancer

Failed

Discontinued

Gavo-cel (TC-210) (Mesothelin) + nivolumab Details
Solid tumor/s, Ovarian cancer, Cancer

Failed

Discontinued